Chengwei Zhang

Nanjing University, Nanjing Drum Tower Hospital

Papers

3

Total Citations

100

H-Index

2

About

Chengwei Zhang is a leading urologic oncology researcher whose work centers on improving the diagnosis and surgical management of prostate and bladder cancers. His landmark 2017 study comparing 68Ga-PSMA-11 PET-CT with multiparametric MRI for preoperative lymph node staging in intermediate to high-risk prostate cancer—cited 96 times—has significantly advanced preoperative imaging accuracy, guiding more precise surgical planning. Zhang’s contributions extend to artificial intelligence, where his 2024 work on deep neural networks for prostate cancer pathological diagnosis demonstrates exceptional diagnostic accuracy, signaling a transformative shift toward AI-assisted pathology. He has also investigated renal function outcomes following robot-assisted radical cystectomy, revealing that intracorporeal urinary diversion may delay postoperative renal injury—a finding with direct implications for surgical decision-making in bladder cancer patients. With a research portfolio that bridges cutting-edge imaging, AI diagnostics, and minimally invasive surgical techniques, Zhang is shaping the future of precision urologic oncology. His work continues to influence clinical guidelines and inspire further innovation in cancer care.

Research Focus

Key Achievements

2
H-Index
3
Papers
100
Total Citations
33
Avg Citations/Paper
🏆 Most Cited Paper
Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer
96 citations · 2017
📈 Most Prolific Year: 2024 (2 Papers)
🤝 Key Collaborators: 28
🏛 Institutions: Nanjing University, Nanjing Drum Tower Hospital

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago